EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The effect of COVID-19 vaccination on anticoagulation stability in adolescents and young adults using vitamin K antagonists

Chantal Visser, Arjen Yousefi, Melchior C Nierman, Menno V Huisman, Anouk J W Gulpen, C Heleen van Ommen, Marieke J H A Kruip, Dutch COVID and Thrombosis Coalition

Thrombosis Research · 2023

DOI: 10.1016/j.thromres.2023.06.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thrombosis Research, 2023. Verfasst von Chantal Visser und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Erasmus MC, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: COVID-19 Vaccines, COVID-19. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Netherlands Organisation for Health Research and Development, Trombosestichting Nederland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: The European Medicine Agency has authorized COVID-19 vaccination in adolescents and young adults (AYAs) from 12 years onwards. In elderly vitamin K antagonist (VKA) users, COVID-19 vaccination has been associated with an increased risk of supra- and subtherapeutic INRs. Whether this association is also observed in AYAs using VKA is unknown. Our aim was to describe the stability of anticoagulation after COVID-19 vaccination in AYA VKA users. MATERIALS AND METHODS: A case-crossover study was performed in a cohort of AYAs (12-30 years) using VKAs. The most recent INR results before vaccination, the reference period, were compared with the most recent INR after the first and, if applicable, second vaccination. Several sensitivity analyses were performed in which we restricted our analysis to stable patients and patients without interacting events. RESULTS: 101 AYAs were included, with a median age [IQR] of 25 [7] years, of whom 51.5 % were male and 68.3 % used acenocoumarol. We observed a decrease of 20.8 % in INRs within range after the first vaccination, due to an increase of 16.8 % in supratherapeutic INRs. These results were verified in our sensitivity analyses. No differences were observed after the second vaccination compared to before and after the first vaccination. Complications after vaccination occurred less often than before vaccination (9.0 vs 3.0 bleedings) and were non-severe. CONCLUSIONS: the stability of anticoagulation after COVID-19 vaccination was decreased in AYA VKA users. However, the decrease might not be clinically relevant as no increase of complications nor significant dose adjustments were observed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19 VaccinesCOVID-19HumansMaleYoung AdultAdolescentAgedAdultFemaleCross-Over StudiesAnticoagulantsInternational Normalized RatioVitamin K

Stichwörter der Autor:innen

AcenocoumarolAdolescentCOVID-19 vaccinesPhenprocoumonYoung adult

Substanzen

COVID-19 VaccinesAnticoagulantsVitamin K

Autor:innen und Institutionen

  • Department of Hematology, Erasmus MC, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands.
  • Department of Thrombosis and Anticoagulation, Atalmedial Medical Diagnostics Centers, Amsterdam, the Netherlands.
  • Department of Medicine - Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands.
  • Department of Internal Medicine, The Elkerliek Hospital, Helmond, the Netherlands.
  • Department of Pediatric Hematology, Erasmus MC Sophia Children's Hospital, Rotterdam, the Netherlands.
  • Department of Hematology, Erasmus MC, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands; Thrombosis Service Star-shl, Rotterdam, the Netherlands. Electronic address: m.kruip@erasmusmc.nl.

Förderung

  • Netherlands Organisation for Health Research and Development
  • Trombosestichting Nederland

Zitieren

APA

Visser, C., Yousefi, A., Nierman, M. C., Huisman, M. V., Gulpen, A. J. W., van Ommen, C. H., Kruip, M. J. H. A., & Dutch COVID and Thrombosis Coalition (2023). The effect of COVID-19 vaccination on anticoagulation stability in adolescents and young adults using vitamin K antagonists. Thrombosis Research. https://doi.org/10.1016/j.thromres.2023.06.005

Vancouver

Visser C, Yousefi A, Nierman MC, Huisman MV, Gulpen AJW, van Ommen CH, et al. The effect of COVID-19 vaccination on anticoagulation stability in adolescents and young adults using vitamin K antagonists. Thrombosis Research. 2023. doi:10.1016/j.thromres.2023.06.005

BibTeX
@article{Visser2023,
  author = {Visser, Chantal and Yousefi, Arjen and Nierman, Melchior C and Huisman, Menno V and Gulpen, Anouk J W and van Ommen, C Heleen and Kruip, Marieke J H A and Dutch COVID and Thrombosis Coalition, Dutch COVID and Thrombosis Coalition},
  title = {The effect of COVID-19 vaccination on anticoagulation stability in adolescents and young adults using vitamin K antagonists},
  journal = {Thrombosis Research},
  year = {2023},
  doi = {10.1016/j.thromres.2023.06.005}
}
Kostenlos starten →